Microsoft word - shoemakercv.doc

Curriculum Vitae
Ritchie C. Shoemaker, M.D.
DOB: 06-13-51 Charlotte N.C. US Citizen
Home address: 2448 Lakeland Drive, Pocomoke, Maryland 21851
Current Employment
Ritchie C. Shoemaker MD. PA. DBA Chronic Fatigue Center
President, ChronicNeurotoxins, Inc
Medical Director, Center for Research on Biotoxin Associated Illnesses (501-c-3, non-profit corp.)

College: Duke University
1969-1973 Magna Cum Laude
Major in Molecular Biology, Zoology. Minor in Philosophy.
• Microtubule control of phototactic responses in Euglena, 1971. • Localization of DNA replication sites in Tetrahymena by electron microscopy, autoradiography
Medical School: Duke University 1973-77

Editor – “First Contact” Medical Student Primary Care Journal
• Molecular basis for muscle injury and repair 1974 • Ventilation-perfusion abnormalities in chronic lung disease 1975 • Epidemiology of streptococci 1976
Residency 1977-80
Family Practice Residency, The Williamsport Hospital, 777 Rural Ave, Williamsport, PA 17013
Board Certification ABFP 1980
MD License 1980 to present. D24924
Professional Memberships
• American Society of Bariatric Physicians 1998-2001 • American Academy of Family Physicians 1999-2001 • American Society for Microbiology 1999-present • American College of Occupational and Environmental Medicine 2/6/05-2/6/06 • American Society of Tropical Medicine and Hygiene 11/05-present • International Lyme and Associated Disease Society (ILADS) 2000-2003 • International Association for Chronic Fatigue Syndrome 4/05-present • Maryland Medical Chirurgical Association (Med Chi) 1980-present • Maryland Academy of Family Physicians 1999-2001 .
Practice Experience
• 7/1980-9/1982 NHSC Pocomoke, Maryland. • 10/1982 to present, Private Practice, Pocomoke, Maryland 500 Market Street, Suites 102,103 5/2002-present

Teaching Appointments

• Milton Hershey Medical School 1980-90, Physician Assistant Preceptor; • Johns Hopkins Medical School 1981-86; • Duke University Medical School 1983-85; • Wilmington College Nurse Practitioner Program 1996-1997; • University of Maryland Medical School 1997-present. NB: These appointments are for community preceptorships only and are not salaried
Hospital Affiliation
, Active Staff, McCready Hospital, Crisfield, Maryland 1980-1986; 1997-6/2003, courtesy
1986-1997; and 7/2003-present, pure outpatient practice (no demands to reduce privileges).
Medical Society
• President, Somerset County 1998-present Credentialed By
• Medicare, Medicaid, BCBS, MDIPA, DHP, Alliance, Prudential, Principal, Aetna American Health Care, Infor Med, PHCS, Trigon, many others.
Additional work experience
Shoemaker’s Bench, Antique Refinishing and Restoration 1966-present. Historic Remodelers of the Eastern Shore 1981-present. Wetland Consultant 1983-present. Visiting Medical Lecturer 1991-present. Website 4/00-present 10/04-present
Books published
• Pandora Boxer (philosophy) 1972 (out of print) • Hematology for Residents 1978 (out of print) • Weight Loss and Maintenance; My Way Works, Does Yours? First printing 1996; Second printing 1998. First printing 1997; Second printing 1998 First printing 2/02; Second printing 10/05 • Mold Warriors 4/05; second printing 12/2007 A Users Guide to Native Shrubs and Trees of the Eastern Shore From Farm to Estuary; A Chesapeake Bay Ecology Cookbook It’s a Long Way From Pocomoke; This One’s For You, Jack. Surviving Mold: Life in the Era of Dangerous Buildings
Columnist Worcester County Messenger weekly newspaper; “What’s Cooking” 1994-2001
Editorials Published
Daily Times of Salisbury (many), Maryland Environmental Health Newsletter,
Outlook (op-ed) Washington Post, Baltimore Sun, Multiple Florida Newspapers,
Runoff Magazine, CCA Journal, Feature article with Duke Alumni Magazine,
Family Practice News, Internal Medicine News, OB-GYN News, Delmarva Farmer (many), Asbury (NJ) Press
National television appearances
Good Morning America, BBC, Australian Broadcasting System, NBC News, CBS News, Discovery Health
Channel: “Dangerous Catch” and “Is Your House out to Get You;” CNN, ABC News
Local TV stations
Multiple: Salisbury, Md., Washington, DC, Baltimore, Md, Stuart, Florida, Philadelphia, Pa, Leesburg, Florida,
New Orleans, Louisiana


• “The Death of Edgar Allen Poe” What Really Happened MMJ 4/97 • Diagnosis of Pfiesteria Human Illness Syndrome, Maryland Medical Journal 1997; 46(10): 521-3. • Treatment of Persistent Pfiesteria Human Illness Syndrome, MMJ 1998; 47(7): 64-66. • Co-author, Grattan et al, Lancet 1998; 352: 532-41. Learning and memory difficulties after environmental exposure to waters containing Pfiesteria or pfiesteria-like dinoflagellates. • Hippocrates 2000; February, Viewpoint Housecall: A crisis in the air restores a physician’s faith in • Possible Estuary-Associated Syndrome, Environmental Health Perspectives 2001; 109(5): 539-545. • Residential and Recreational Acquisition of Possible Estuarine Associated Syndrome: A New approach to Successful Diagnosis and Therapy, Environmental Health Perspectives, Special CDC Pfiesteria Supplement, 2001; 109S5; 791-796. • How Sick is Your Building and What You can do About it, Filtration News, June, 2001 • Getting Inside Sick Building Syndrome, Filtration News, July, 2001 • American Diabetes Association, Diabetes 2002; 51(2) Supplement: A133. Use of pioglitazone to prevent intensification of persistent symptoms following cholestyramine treatment of patients with Post-Lyme syndrome • A Primer in Sick Building Syndrome: Lessons from the Somerset County District Court, Filtration • Lyme Times 2002; 33: 13-16. Lyme, an Infectious Disease and a Neurotoxin Illness. • Lyme Times 2002; 33: 38-40. Someone Has to Tell; a patient’s story. • Environmental Health Perspectives 2002; 110: A121-A123, letter. Visual contrast sensitivity, response. • Environmental Health Perspectives 2003; 111(1): A18-19, letter. Neuropsychologic Testing versus • Medical Conditions Arising From Environmental Conditions, interview, Filtration News, July 2003 • Moldy buildings: It’s a jungle in there. Filtration News, Nov 2004 • Neurotoxicology and Teratology, January 2005. R. Shoemaker and D. House, A time-series of sick building syndrome; chronic, biotoxin-associated illness from exposure to water-damaged buildings. Neurotoxicology and Teratology 2005; 27(1) 29-46. • Sick Building Syndrome in water-damaged buildings: Generalization of the chronic biotoxin-associated illness paradigm to indoor toxigenic fungi; 5/2005; Pg 66-77 in Johanning E. Editor, Bioaerosols, Fungi. Bacteria, Mycotoxins and Human Health. R Shoemaker, JM Rash, EW Simon. • To Build a Safe House, Filtration News, June 2005 • Defining Sick Building Syndrome in adults and children in a case-control series as a biotoxin-associated illness: diagnosis, treatment and disorders of innate immune response, MSH, split products of complement. IL-1B, IL-10, MMP9, VEGF, autoimmunity and HLA DR; American Society of Tropical Medicine and Hygiene; 12/14/05 • C3a and C4a: complement split products identify patients with acute Lyme disease; ASTMH, 12/4/05 • MMP9, visual contrast sensitivity, C3a, C4a and HLA DR: New diagnostic aids in acute and chronic • Atovaquone plus cholestyramine in patients co-infected with Babesia microti and Borrelia burgdorferi refractory to other treatment, Advances in Therapy 2006; 23(1): 1-11. Shoemaker RC, Hudnell KH, House DE, van Kempen A, Pakes GE for the COL 40155 Study Team. • American Society for Microbiology Biodefense Research meeting 2/16/06 Hyperacute physiological changes following prospective exposures to environmental sources of trichothecene toxins in water-damaged buildings (WDB): a Stealth toxin is revealed. • SBS and exposure to water damaged buildings: time series study, clinical trial and mechanisms; submitted, Neurotoxicology and Teratology 3/27/06, accepted for publication 7/31/06. R Shoemaker, D House. Internet location: doi: 10.1016/ Published as NTT 2006; 28: 573-588. • Mold Illness after Katrina: The truth you haven’t heard. Filtration News, May, June 2006 • AAAAI; rebuttal to Bush position paper, endorsed by >100 PhD and MDs; submitted 5/06, accepted 7/8/06, JACI 2006; 118: 764-766. Co-authors: Harriett Ammann PhD; Richard Lipsey PhD; and Ed Montz PhD. • ASTM International, Section D22, Boulder Colorado 7/27/06. Bringing science to bear on moisture and mold in the built environment. “Defining causality of a biotoxin-associated illness by exposure to water-damaged buildings: a case control series.” • ASTMH 11/06 (accepted) Defining chronic ciguatera illness by abnormalities in innate immune responses: final common pathways of biotoxin-associated illnesses • ASTMH 11/06 (accepted) Eight year follow-up of patients with Possible Estuarine Associated Syndrome (PEAS): symptom reduction didn’t result in cure • International Association for Chronic Fatigue Syndrome 1/14/07. Treatment of elevate C4a in patients with CFS using low doses of erythropoietin safely reduces symptoms and lowers C4a: a prospective clinical trial. • International Association for Chronic Fatigue Syndrome 1/14/07. Treatment of CFS patients with elevated C4a using low dose erythropoietin corrects abnormalities in central nervous system metabolites and restores executive cognitive functioning. • International Association for Chronic Fatigue Syndrome 1/14/07. Treatment of CFS patients with low levels of vasoactive intestinal polypeptide (VIP) and shortness of breath with tadalafil improves exercise tolerance and pulmonary artery pressure responses to exercise. • Inside Indoor air quality 4/15/07, with King-teh Lin PhD. Filtration News May/June 2007. • 10/3/07 Allergy Clin Immunol Int: J World Allergy Org 2007 Supplement 2. C3a and C4a: Complement split products identify patients with hyperacute Lyme disease. • 10/14/07 IAQA, Las Vegas, Nevada. Sequential activation of innate immune elements: a health index for people re-exposed to water-damaged buildings. • ASTMH 11/07. Correction of central nervous system metabolic abnormalities, deficits in executive cognitive functioning and elevated C4a: a clinical trial using low dose erythropoietin in patients sickened by exposure to water-damaged buildings. • ASTMH 11/07. Sequential upregulation of innate immune responses during acute acquisition of illness in patients exposed prospectively to water-damaged buildings. • ASTMH 11/07. Defining mold illness in children: a chronic inflammatory illness with distinctive • International Archives of Allergy and Immunology, 2008; 146: 255-261. C3a and C4a define acute Lyme disease. Shoemaker RC, Giclas P, Glovsky M. • Indoor Environmental Communications 1/08. Shoemaker RC and Lin, Kin-the. The ever-expanding data base on pathophysiology of illness caused by exposure to water-damaged buildings.
Peer reviewer:
Environmental Health Perspectives; Special CDC Pfiesteria issue, 2001; comment on fungal illness 2007 Journal of Nutritional and Environmental Medicine 2007 (small colony variants. MARCoNS) Heart and Lung 2007 (Babesia as FUO) Health Policy. 2/08. The relationship between sick building syndrome and perceived indoor environmental quality in apartment buildings
Graduate degree examiner
University on Newcastle, Australia 10/04. Delta hemolysins production of long-term Staphylococcus epidermidis cultures. Hai Lin, Environmental and Life Sciences.

4/10/00 Regional Meeting American Society of Microbiology, Lewes, Delaware.
A new approach to diagnosis and treatment of chronic Lyme disease: vision, cytokines, and cholestyramine. • 5/10/00- Chico, Calif. Lyme disease as a Neurotoxin and Cytokine-Mediated Illness
9/21/00 Lewes, Delaware. Center for the Inland Bays “Pfiesteria Human Illness Syndrome and Blue
Green Algae Syndrome: Emerging Estuarine Health Threats” • 9/24-25/00 Tallahassee, Florida. Florida Department of Environmental Protection Diagnosis and
Treatment of a chronic neurotoxin-mediated illness from an unknown microbe at the Casteen Roads. • 11/4/00, Princeton, New Jersey. Annual Scientific Conference of the Lyme Disease Association
Hypoperfusion of retina and neural rim of optic nerve head as biomarker for the chronic neurotoxin-mediated illness of Lyme disease. • 10/25/00 American Psychiatric Association, Annual Meeting, Philadelphia, PA. Environmental
10/30/00 Annual Meeting of American Society of Tropical Medicine and Hygiene, Houston, Texas.
A new approach to diagnosis of chronic ciguatera illness and successful treatment with cholestyramine • 6/01/01 Delaware Medical Society, Lewes, Delaware. Approach to Diseases Caused by Neurotoxins
11/09/01 Lyme Disease Association, Princeton, NJ. Acute Lyme Disease
11/10/01 ILADS. Princeton, NJ, Co-infection with apicomplexans and Lyme, role of extrachromosomal
11/30/01 International Society of Neurobiology, Seattle, Washington. Neurotoxins and solutions to
questions raised by chronic fatiguing illnesses • 2/14/02 American Academy of Environmental Medicine, St. Louis, Missouri, an 8 hour tutorial.
Challenges to Clinical Paradigms: Cytokines, neurotoxins and vision • 6/24/02 8th International Symposium of Neurotoxicology, Brescia, Italy. Co-Chair (with Ken Hudnell,
Ph.D.) of Biotoxin Session. Three lectures: Sick Building Syndrome: Possible Association with Exposure to Mycotoxins from Indoor Air Fungi (to date, the largest study on SBS in the world’s literature, 103 patients and 43 buildings); Use of pioglitazone to prevent intensification of persistent symptoms following cholestyramine treatments of patients with Post-Lyme Syndrome: the multisite trial. Metallic Taste, a marker of neurotoxicity. • 9/17/02 Environmental and Occupational Health Sciences Institute, Occupational Medicine Residency
Program, Robert Wood Johnson Medical School, Piscataway, NJ; Neurotoxin mediated illnesses: A new approach to medically unexplained symptoms. • 9/20/02 International College of Integrative Medicine, Grand Rapids, Michigan. Neurotoxins,
hypothalamic hormones and chronic fatiguing illnesses • 11/15/02 ASTMH Denver, Colo, Use of atovaquone and cholestyramine in patients co-infected with
Borrelia burgdorferi and Babesia microti, refractory to all antibiotic regimens (GlaxoSmithKline funded research). • 12/6/02 Faculty member, National panel, Wright State University, Michigan. Interim clinical guidelines
for the diagnosis and treatment of mold associated medical disorders; presented, “A new paradigm for diagnosis and treatment of Sick Building Syndrome, a biotoxin associated illness.” • 2/20/03 Univ Connecticut, Pathobiology seminar, “Biotoxins, vision, inflammatory cytokines and
hypothalamic hormones in primary care medicine: From Post-Lyme Syndrome to Sick Building Syndrome, a new paradigm for medically uncertain symptoms. • 7/11/03 Harris Chain of Lakes Restoration Commission, Lake County, Florida. St. John’s River
Water Management District, invited lecture: Human health effects following exposure to toxigenic cyanobacteria: diagnosis, treatment and environmental implications • 9/10/03 5th International Conference on Bioaerosols, Fungi, Bacteria, Mycotoxins and Human
Health, Saratoga Springs, NY (peer reviewed). Sick building syndrome in water damaged buildings:
Generalization of the chronic biotoxin associated illness paradigm to indoor toxigenic fungi (156
patients in 150 buildings).
9/25/03 13th annual Environmental Information Association. Myrtle Beach, SC, keynote. The clear
link between mold exposure and human health: What you need to know • 10/30/03 Mold 5 National Institute of Building Sciences, Building envelope and thermal
environment committee, San Diego, Cal, keynote, Human health effects from exposure to toxigenic
fungi: The proof of causation is here.
11/25/03 Crossing boundaries: Medical Biodefense and Civilian/Military Medicine; First
International conference, sponsored by George Mason University, National Center for Biodefense
and Georgetown University,
Arlington, Va. Diagnosis and Treatment of Biotoxin Associated Illnesses:
Learning for the future from Today’s Example
12/02/03 Special Report to the Federal Research Committee on Gulf War Illness. Gulf War Illness
as a Biotoxin Illness: Report of a cohort of exposed veterans. • 1/10/04 Invited speaker, National Center for Biodefense, George Mason University. Physiology of
4/30/04 American Society for Microbiology, Integrating Metabolism and Genomics, Montreal,
Quebec. Linkage disequilibrium of HLA DR genotypes, autoantibodies and wingspan/height ratios in patients with environmentally acquired toxigenic illness • 5/25/04 104th General meeting of American Society for Microbiology, New Orleans, Louisiana.
Melanocyte Stimulating Hormone (MSH) Deficiency in Chronic Fatigue Syndrome Associated with Nasal Carriage of Coagulase Negative Staphylococci • 6/22-23 2004 Mealey’s National Mold Litigation Conference, Orlando, Florida. Invited speaker,
Emerging medical issues in mold illness. • 10/8/04 American (now International) Association for Chronic Fatigue Syndrome, Madison,
Wisconsin. Chronic Fatigue Syndrome: Lessons from the Biotoxin Pathway • 12/4/04 Johns Hopkins University, Occupational and Environmental Medicine Conference,
Chronic Illness from Water-Damaged Buildings: Just Another Stop Along the Biotoxin Pathway • 12/9-10/04 Mealey’s Construction Defect and Mold Litigation Conference, Las Vegas, Nevada,
Why the Institute of Medicine Report is Stale • 9/6-10/05 International Symposium on Cyanobacteria and Harmful Algal Blooms, US EPA
Research Triangle Park, NC. Characterization of chronic human illness associated with exposure to cyanobacterial harmful algal blooms predominated by Microcystis 11/2/05 Mid-Shore Lyme Disease Association, Acute and chronic Lyme disease: lessons from the
Biotoxin Pathway. Easton, Maryland. 2/16/06 Drexel University School of Medicine, Philadelphia, Pa. Visiting professor series. It’s a
3/4/06 CAM Expo East, NYC, NY. Physiology of fibromyalgia and Chronic Fatigue Syndrome
3/25/06 Mid-Shore Lyme Disease Association, Easton, Md. Rise of the innates; Lyme disease
4/1/06 Third Annual Mold Conference, Houston, Texas. Mold Illness: So What do We Really Know?
5/6/06 American College for Advancement in Medicine, Dallas Texas. Lyme disease update: Rise of the
6/28/07 Quarterly Medical Director’s Conference; Department of Mental Health Services, State of
Virginia, “Inflammatory central nervous system illness caused by environmental exposures presenting as psychiatric illness.” • 8/6/07 International CFS leaders conference, Sonoma County, California. “Shoemaker for dummies.”
12/6/07 National Toxicology Program NIEHS, RTP, NC. Physiologic disturbances and causality in
patients with illness acquired following exposure to water-damaged buildings • 4/12/08 Lyme and autism, LIA Foundation, “What biotoxins do to inflammation and brains.” Fort Lee,
6/2/08 AIHA continuing education program Round Table, Minneapolis; Steve Vesper, Greg Boothe, Gil
Cormier King teh Lin co-panelists. Integrating Field, Laboratory and Clinical data for the IAQ investigation. Comparison of indices of human health and building healthy: SAIIE meets ERMI. • 6/15/08 7th International Conference on Neurotoxiology, Costa Rica. Human health effects of acute and
chronic exposure to toxigenic cyanobacteria. EPICOH-NEUREOH.

Georgetown Center for Food Policy, Washington, D.C. 1. Pfiesteria; Diagnosis and Treatment 2. Environmental Factors Contributing to Pfiesteria Blooms Maryland Academy of Family Practice Annual Meeting 1. Pfiesteria Human Illness Syndrome 2. Use of Troglitazone in Treatment of Hyperinsulinemic Obesity Association of Research in Vision and Ophthalmology, Fort Lauderdale, Florida. 1. Use of Contrast Sensitivity in Diagnosis of Chronic Neurotoxin-Mediated Illness US EPA National Health and Environmental Effects and Research Lab 1. Human Health and Environmental Indicators 2. Possible Estuarine Associated Syndrome, Diagnosis and Treatment 10/18/00
CDC National Pfiesteria Conference Stone Mountain, Georgia 1. Evidence of Successful treatment of the chronic neurotoxin-mediated illness of Possible 2. Possible Cylindrospermopsis Associated Human Illness Syndrome 81st Meeting of Endocrine Society, Denver, Colorado 1. Use of Rosiglitazone in Treatment of Hyperinsulinemic Obesity (SmithKlineBeecham San Francisco, American Diabetes Association 1. Use of Pioglitazone to Prevent Intensification of Persistent Symptoms following Cholestyramine Treatment of Patients with the Post-Lyme Syndrome (Takeda Pharmaceuticals North America, funded research) 11/15/02
Denver, Colorado, ASTMH 1. Differential Association of HLA DR by PCR Genotypes with Susceptibility to Chronic, 9/10-9/12/03
Saratoga Springs, NY 5th International Conference on Bioaerosols, Fungi. Bacteria, Mycotoxins and Human Health. 1. Sick Building Syndrome, diagnosis and treatment of a biotoxin associated illness with multiple biomarkers: prospective confirmation of causation in 156 patients from 150 buildings using 11 different biomarkers American Association for Chronic Fatigue Syndrome, Madison, Wisconsin 1. Chronic Fatigue Syndrome: Lessons from the Biotoxin Pathway;
CME Speaker:

Maryland Academy of Osteopathic Physicians, Ocean City, Maryland Annual Meeting. 1. A physician’s approach to diagnosis and treatment of chronic neurotoxin-mediated American Society of Bariatric Physicians:
Phoenix, Arizona Regional Meeting 1. Use of troglitazone in treatment of hyperinsulinemic obesity. 10/30/99
Las Vegas, Nevada. Annual Meeting 1. Rational use of the Glycemic Index 5/10/00 Portland, Oregon, Regional Meeting
1. Environmental acquisition of defects in insulin receptor physiology Washington, D.C. Annual Meeting 1. Hypoperfusion, tumor necrosis factor alpha and environmental acquisition of diabetes and Houston, Texas. 1. Use of Rosiglitazone in treatment of Hyperinsulinemic Obesity in Non-Diabetics WV Academy of Physician Assistants, Davis, WV. 1. The No-Amylose Diet
Congressional testimony: House of Representatives 9/22/04 staff briefing and press conference Member John
Conyers; Health effects of exposure to water-damaged buildings; US Senate staff meeting 1/12/06, Human health
effects of mold exposure, Senator Edward Kennedy.
Maryland Senate testimony: Commentary on indoor air quality task force at invitation of Senator Rob
Garagiola 3/29/06

IRB Studies

Use of rosiglitazone in treatment of hyperinsulinemic obesity. b. Glaxo Wellcome 10/00 IRB: Copernicus Group Use of Mepron (atovaquone) in patients with Borrelia burgdorferi coinfected with Babesia microti refractory to antibiotics and cholestyramine. c. Protocol IND 63,993 Use of Melanocyte Stimulating Hormone in Patients with Chronic Fatigue d. Protocol SBS 51326 Use of visual contrast sensitivity testing and cholestyramine therapy in diagnosis and treatment of environmentally-acquired, chronic, neurotoxin-mediated illness from indoor exposure IRB Copernicus 7/23/02 e. SPL-CFS 123 Treatment of Chronic Fatigue Syndrome in patients with nasal colonization of multiply antibiotic resistant, biofilm-forming species of coagulase negative Staph using nasal instillation of diluted Staphage Lysate® IRB Copernicus 11/27/03 Retrospective use of laboratory results in a report of group results: Complement split products C3a, C4a, MMP9 and visual contrast sensitivity are markers for acute acquisition of Lyme disease. IRB Copernicus Group, 9/8/05 g. Retrospective use of individual laboratory results in a report of group results: Defining Sick Building Syndrome in adults and children as a biotoxin-associated illness. IRB Copernicus Group 10/20/05 h. Retrospective use of individual laboratory results in a report of group results: Eight-year follow-up of Possible Estuarine Associated Syndrome cases and controls. IRB Copernicus Group 11/7/05 Lecturer Medical Mutual Insurance Company 2/00 Risk Management in Primary Care


• American Academy of Family Practice, Finalist, National Family Practice Physician of the Year, 2002 • Maryland Family Practice Doctor of the Year 2000, MAFP • Maryland Governor’s Volunteer of the Year for the Environment, 4/97 • Local Governor’s Advisory Committee for Innovation and Restoration of Chesapeake Bay 1994 • State of Maryland Bill Jones Environmental Award 1995 • Maryland Dept. Agriculture Conservator of the Year 1994 • Dr. Henry P. and M. Page Laughlin Award for Distinguished Authorship/Editorial Award 5/98
Commencement Speaker

• Malcolm Grow Medical Center (Andrews AFB 6/98)
CME Speaker

• Audio Digest Vol. 47 No. 22 6/99 Washington D.C. • Audio Digest Vol. 48 No. 14 12/99 Washington D.C.
Internet links

• • http:// www.
Patents applications, provisional

• PAI-1 and TNF as markers for the inflammatory basis of type II diabetes, obesity and atherosclerosis. US Provisional patent Serial no 60/356,541 • Use of alpha melanocyte stimulating hormone to treat patients with chronic fatigue syndrome. US Patent Provisional Serial no.: 60/356/539. • Use of thiazolidinediones as an adjunct to diet in treatment of hyperinsulinemic obesity; importance of the No-Amylose diet. US Patent Provisional Serial no.: 60/356,690 • Pretreatment of patients with Post-Lyme Syndrome with pioglitazone before use of cholestyramine prevents intensification: Vision, neurotoxins and cytokines. US Patent Provisional Serial no.: 60/333,335
Completed Patent application

• “Methods for treating or inhibiting Sick Building Syndrome, Post-Lyme Syndrome, and/or Chronic Fatigue Syndrome.” Inventors Ritchie Shoemaker MD and H. Kenneth Hudnell, Ph.D. PCT Patent application no PCT/US03/04137
Health Investigations and treatment, cohorts of patients exposed to toxigenic fungi (> 4 patients)

• Glenwood Springs, Colorado. Robert Cordova, leader of cohort. 7/28/06 14 patients. • Fraternal Order of Police; Queen Anne’s County, Maryland 5/06 8 patients • St. Bernard Parish, Louisiana, on the Scotia Prince 2/06; conjoint investigation with Richard Lipsey, PhD; firefighters, homeless adults and children, Parish employees, ship’s crew and health care workers 212 patients • Residences at the Ritz; Ritz Carlton 1155 and 1111 23rd St NW Washington DC 8 patients • Newmarket Courthouse, Toronto, Ontario, Canada. 12/04-present; 300 employees at risk • International Marine Terminal, Portland, Maine. 11/05. 16 patients. • Topsail (NC) School District. 9/04. 260 patients. • Prince Georges County Fraternal Order of Police; Oxon Hill, Md. 6/03. 52 patients. • Hampton Bays United Free Elementary School, Long Island, NY. 5/03. 44 patients. • State Iowa Dept Corrections, Davenport, Iowa. 1/03. 10 patients. • Baltimore-Washington Conference United Methodist Church, Columbia, Md. 12/02. 55 patients • Eastern Correctional Institution, Westover, Md. 5/02. 11 patients.
• Accomack County (Virginia) Social Services Building. 4/02. 11 patients. • Multi-Services Building 201 Baptist St., Salisbury, Md. 4/02. 20 patients. • Police Department Berlin, Md. 4/02. 5 patients. • Somerset County Library, Princess Anne, Md. 2/02. 13 patients. • Somerset County Circuit Court, Princess Anne, Md. 10/01. 5 patients. • Somerset County District Court, Princess Anne, Md. 6/01. 12 patients. • Worcester County Board of Education Newark, Md. 5/99. 8 patients. • Wicomico County Sheriffs Department, Salisbury, Md. 2/99. 25 patients.
Papers in preparation
• Biofilm formation makes multiply antibiotic resistant coagulase negative staphylococci pathogens in low • Pediatric mold illness: inflammatory links to autoimmunity • HLA in illness and disease: equilibrium dissociation and biotoxin illness susceptibility


OCCURRENCE AND RISK ASSESSMENT OF PHARMACEUTICAL SUBSTANCES IN THE GREAT LAKES BASIN Merih Otker Uslua,b, Saad Jasima,b, Antonette Arvaia , Jatinder Bewtrab, Nihar Biswasb aGreat Lakes Regional Office, International Joint Commission, Windsor, Ontario, Canada bCivil and Environmental Engineering, University of Windsor, Windsor, Ontario, Canada ABSTRACT Pharmaceutical substan


Aggiornamento normativo del mese di febbraio 2009 Scadenze dichiarazioni redditi: Sono state emanate le scadenze definitive delle prossime dichiarazioni di redditi: ƒ modello 730 consegna documenti allo studio entro il 1 giugno 2009 (trasmissione all’agenzia delle entrate il 15 luglio 2009) influirà sulle ritenute di “competenza” del mese di luglio 2009;ƒ modello unico (socie

Copyright © 2010 Health Drug Pdf